Twist Bioscience (NASDAQ:TWST) CFO Sells $350,000.00 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 7,000 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $50.00, for a total value of $350,000.00. Following the transaction, the chief financial officer owned 130,031 shares of the company’s stock, valued at $6,501,550. The trade was a 5.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Adam Laponis also recently made the following trade(s):

• On Tuesday, January 13th, Adam Laponis sold 3,000 shares of Twist Bioscience stock. The shares were sold at an average price of $40.00, for a total transaction of $120,000.00.
• On Friday, January 9th, Adam Laponis sold 2,738 shares of Twist Bioscience stock. The shares were sold at an average price of $35.26, for a total transaction of $96,541.88.

Twist Bioscience Stock Up 3.0%

Shares of Twist Bioscience stock opened at $49.11 on Monday. The company has a 50-day simple moving average of $38.63 and a two-hundred day simple moving average of $32.45. The stock has a market capitalization of $3.01 billion, a PE ratio of -38.37 and a beta of 2.24. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $51.00. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.37 and a current ratio of 3.78.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The firm had revenue of $103.70 million for the quarter, compared to the consensus estimate of $100.32 million. Twist Bioscience’s quarterly revenue was up 16.9% compared to the same quarter last year. On average, analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TWST has been the subject of several research analyst reports. Stephens assumed coverage on Twist Bioscience in a report on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price objective for the company. Barclays raised their price target on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday, February 3rd. Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Finally, Evercore raised their target price on shares of Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a report on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and an average target price of $45.88.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors have recently made changes to their positions in the business. Stifel Financial Corp increased its holdings in Twist Bioscience by 3.6% during the fourth quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock valued at $246,000 after buying an additional 271 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Twist Bioscience by 83.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,955 shares of the company’s stock worth $63,000 after acquiring an additional 887 shares during the last quarter. Van ECK Associates Corp grew its position in shares of Twist Bioscience by 99.2% during the 4th quarter. Van ECK Associates Corp now owns 2,076 shares of the company’s stock valued at $66,000 after acquiring an additional 1,034 shares during the period. State Street Corp increased its stake in shares of Twist Bioscience by 17.4% in the 4th quarter. State Street Corp now owns 3,627,818 shares of the company’s stock worth $115,074,000 after purchasing an additional 538,755 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Twist Bioscience by 4.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,173,100 shares of the company’s stock worth $37,211,000 after purchasing an additional 49,403 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.